Citations

Clear

5212 citation(s) found for "Wang, Li-Ju".

Evaluation of vitamin D biosynthesis and pathway target genes reveals UGT2A1/2 and EGFR polymorphisms associated with epithelial ovarian cancer in African American Women
Grant, Delores J. , Alberg, Anthony J. , Barnholtz‐Sloan, Jill S. , Bondy, Melissa L. , Funkhouser, Ellen, Moorman, Patricia G. , Peres, Lauren C. , Peters, Edward , Schwartz, Ann G. , Terry, Paul , Wang, Xin‐Qun, Hoyo, Cathrine , Sandler, Dale P. , Taylor, Jack A. , Edwards, Todd L., Beeghly‐Fadiel, Alicia, Wentzensen, Nicolas , Pearce, Celeste Leigh , Wu, Anna H. , Whittemore, Alice S. , McGuire, Valerie , Sieh, Weiva , Rothstein, Joseph H. , Ness, Roberta B., Moysich, Kirsten B. , Rossing, Mary Anne, Sellers, Thomas A. , Monteiro, Álvaro N.A. , Levine, Douglas A. , Haiman, Christopher A. , Menon, Usha , Ramus, Susan J. , Gayther, Simon A. , Terry, Kathryn L. , Goode, Ellen L. , Cannioto, Rikki , Odunsi, Kunle , Etter, John Lewis , Huang, Ruea‐Yea , Bernardini, Marcus Q. , Tone, Alicia , May, Taymaa, Goodman, Marc T. , Thompson, Pamela J., Carney, Michael E. , Tworoger, Shelley S. , Lambrechts, Diether , Vergote, Ignace , Nieuwenhuysen, Els Van , Salvensen, Helga B., Massuger, Leon F.A.G. , Bruegl, Amanda , Moffitt, Melissa , Le, Nhu D. , Brooks‐Wilson, Angela , Kelemen, Linda E. , Song, Honglin , Eccles, Diana , DeFazio, Anna , Kennedy, Catherine J. , Schildkraut, Joellen M. , Lambrechts, Diether , Barnholtz-Sloan, Jill S , Moysich, Kirsten , Permuth, Jennifer B , Cramer, Daniel W , Fazio, Anna de , Lambrechts, Diether , Ramus, Susan J , Sandler, Dale P , Tworoger, Shelley S , Eccles, Diana , Menon, Usha , Monteiro, Alvaro N , Brooks-Wilson, Angela R , Kennedy, Catherine J , Lambrechts, Diether , Sieh, Weiva , Taylor, Jack A , Goodman, Marc T , Manichaikul, Ani , Bandera, Elisa V. , Coté, Michele L. , Keku, Temitope O , Berchuck, Andrew , O’Brien, Katie M. , Edwards, Digna R. Velez , Beeghly‐Fadiel, Alicia , Modugno, Francesmary , Doherty, Jennifer A. , Permuth, Jennifer B. , Setiawan, Veronica Wendy , Marchand, Loı̈c Le , Wilkens, Lynne R. , Karlan, Beth Y. , Gentry‐Maharaj, Aleksandra , Cramer, Daniel W. , Larson, Melissa C. , Kaufmann, Scott H. , Poole, Elizabeth M. , Vanderstichele, Adriaan , Anton‐Culver, Hoda , Ziogas, Argyrios , Brenton, James D. , Bjørge, Line , Kiemeney, Lambertus A. , Pejovic, Tanja B. , Cook, Linda S. , Pharoah, Paul D.P. , Campbell, Ian

Mayo Clinic

Cancer Medicine | April 19, 2019 | Volume: 8 | Issue: 5 | Pages: 2503-2513

10.1002/cam4.1996 | PMID 31001917 Get It

AbstractAn association between genetic variants in the vitamin D receptor (VDR) gene and epithelial ovarian cancer (EOC) was previously reported in women of African ancestry (AA). We sought to examine associations between genetic variants in VDR and additional genes from vitamin D biosynthesis and pathway targets (EGFR, UGT1A, UGT2A1/2, UGT2B, CYP3A4/5, CYP2R1, CYP27B1, CYP24A1, CYP11A1, and GC). Genotyping was performed using the custom‐designed 533,631 SNP Illumina OncoArray with imputation to the 1,000 Genomes Phase 3 v5 reference set in 755 EOC cases, including 537 high‐grade serous (HGSOC), and 1,235 controls. All subjects are of African ancestry (AA). Logistic regression was performed to estimate odds ratios (OR) and 95% confidence intervals (CI). We further evaluated statistical significance of selected SNPs using the Bayesian False Discovery Probability (BFDP). A significant association with EOC was identified in the UGT2A1/2 region for the SNP rs10017134 (per allele OR = 1.4, 95% CI = 1.2‐1.7, P = 1.2 × 10−6, BFDP = 0.02); and an association with HGSOC was identified in the EGFR region for the SNP rs114972508 (per allele OR = 2.3, 95% CI = 1.6‐3.4, P = 1.6 × 10−5, BFDP = 0.29) and in the UGT2A1/2 region again for rs1017134 (per allele OR = 1.4, 95% CI = 1.2‐1.7, P = 2.3 × 10−5, BFDP = 0.23). Genetic variants in the EGFR and UGT2A1/2 may increase susceptibility of EOC in AA women. Future studies to validate these findings are warranted. Alterations in EGFR and UGT2A1/2 could perturb enzyme efficacy, proliferation in ovaries, impact and mark susceptibility to EOC.
MENDA: a comprehensive curated resource of metabolic characterization in depression
Pu, Juncai , Yu, Yue , Liu, Yiyun , Tian, Lu , Gui, Siwen , Zhong, Xiaogang , Fan, Chu , Song, Xuemian, Liu, Lanxiang , Yang, Lining , Zheng, Peng , Chen, Jianjun , Cheng, Ke , Zhou, Chanjuan, Wang, Haiyang , Xie, Peng , Xu, Shaohua

Mayo Clinic

Briefings in Bioinformatics | April 18, 2019 | Volume: 21 | Issue: 4 | Pages: 1455-1464

10.1093/bib/bbz055 | PMID 31157825 Get It

Abstract Depression is a seriously disabling psychiatric disorder with a significant burden of disease. Metabolic abnormalities have been widely reported in depressed patients and animal models. However, there are few systematic efforts that integrate meaningful biological insights from these studies. Herein, available metabolic knowledge in the context of depression was integrated to provide a systematic and panoramic view of metabolic characterization. After screening more than 10 000 citations from five electronic literature databases and five metabolomics databases, we manually curated 5675 metabolite entries from 464 studies, including human, rat, mouse and non-human primate, to develop a new metabolite-disease association database, called MENDA (http://menda.cqmu.edu.cn:8080/index.php). The standardized data extraction process was used for data collection, a multi-faceted annotation scheme was developed, and a user-friendly search engine and web interface were integrated for database access. To facilitate data analysis and interpretation based on MENDA, we also proposed a systematic analytical framework, including data integration and biological function analysis. Case studies were provided that identified the consistently altered metabolites using the vote-counting method, and that captured the underlying molecular mechanism using pathway and network analyses. Collectively, we provided a comprehensive curation of metabolic characterization in depression. Our model of a specific psychiatry disorder may be replicated to study other complex diseases.
Cell-level somatic mutation detection from single-cell RNA sequencing
Vu, Trung Nghia , Nguyen, Ha-Nam, Calza, Stefano , Wang, Liewei , Kalari, Krishna R. , Pawitan, Yudi

Mayo Clinic

Bioinformatics | April 17, 2019 | Volume: 35 | Issue: 22 | Pages: 4679-4687

10.1093/bioinformatics/btz288 | PMID 31028395 Get It

Abstract Motivation Both single-cell RNA sequencing (scRNA-seq) and DNA sequencing (scDNA-seq) have been applied for cell-level genomic profiling. For mutation profiling, the latter seems more natural. However, the task is highly challenging due to the limited input materials from only two copies of DNA molecules, while whole-genome amplification generates biases and other technical noises. ScRNA-seq starts with a higher input amount, so generally has better data quality. There exists various methods for mutation detection from DNA sequencing, it is not clear whether these methods work for scRNA-seq data. Results Mutation detection methods developed for either bulk-cell sequencing data or scDNA-seq data do not work well for the scRNA-seq data, as they produce substantial numbers of false positives. We develop a novel and robust statistical method—called SCmut—to identify specific cells that harbor mutations discovered in bulk-cell data. Statistically SCmut controls the false positives using the 2D local false discovery rate method. We apply SCmut to several scRNA-seq datasets. In scRNA-seq breast cancer datasets SCmut identifies a number of highly confident cell-level mutations that are recurrent in many cells and consistent in different samples. In a scRNA-seq glioblastoma dataset, we discover a recurrent cell-level mutation in the PDGFRA gene that is highly correlated with a well-known in-frame deletion in the gene. To conclude, this study contributes a novel method to discover cell-level mutation information from scRNA-seq that can facilitate investigation of cell-to-cell heterogeneity. Availability and implementation The source codes and bioinformatics pipeline of SCmut are available at https://github.com/nghiavtr/SCmut. Supplementary information Supplementary data are available at Bioinformatics online.
Living Donor Liver Transplantation: Overview, Imaging Technique, and Diagnostic Considerations
Hecht, Elizabeth M. , Kambadakone, Avinash , Wang, Zhen J. , Fidler, Jeff L. , Griesemer, Adam , Fowler, Kathryn J. , Heimbach, Julie K. , Fidler, Jeff L.

Mayo Clinic

American Journal of Roentgenology | April 11, 2019 | Volume: 213 | Issue: 1 | Pages: 54-64

10.2214/ajr.18.21034 | PMID 30973783 Get It

Living Donor Liver Transplantation: Preoperative Planning and Postoperative Complications
Hecht, Elizabeth M. , Wang, Zhen J. , Kambadakone, Avinash , Fidler, Jeff L. , Griesemer, Adam , Fowler, Kathryn J. , Heimbach, Julie K. , Fidler, Jeff L.

Mayo Clinic

American Journal of Roentgenology | April 11, 2019 | Volume: 213 | Issue: 1 | Pages: 65-76

10.2214/ajr.18.21064 | PMID 30973784 Get It

Clopidogrel Pharmacogenetics
Pereira, Naveen L. , Rihal, Charanjit S. , So, Derek , Rosenberg, Yves , Lennon, Ryan J. , Mathew, Verghese, Weinshilboum, Richard M., Wang, Liewei , Baudhuin, Linnea M. , Hasan, Ahmed , Iturriaga, Erin , Fu, Yi-Ping, Geller, Nancy L. , Bailey, Kent R. , Farkouh, Michael E. , Rihal, Charanjit S. , Lennon, Ryan J. , Goodman, Shaun G. , Lerman, Amir

Mayo Clinic

Circulation: Cardiovascular Interventions | April 11, 2019 | Volume: 12 | Issue: 4 | Pages: No page available

10.1161/circinterventions.119.007811 | PMID 30998396 Get It

Common genetic variation in CYP2C19 (cytochrome P450, family 2, subfamily C, polypeptide 19) *2 and *3 alleles leads to a loss of functional protein, and carriers of these loss-of-function alleles when treated with clopidogrel have significantly reduced clopidogrel active metabolite levels and high on-treatment platelet reactivity resulting in increased risk of major adverse cardiovascular events, especially after percutaneous coronary intervention. The Food and Drug Administration has issued a black box warning advising practitioners to consider alternative treatment in CYP2C19 poor metabolizers who might receive clopidogrel and to identify such patients by genotyping. However, routine clinical use of genotyping for CYP2C19 loss-of-function alleles in patients undergoing percutaneous coronary intervention is not recommended by clinical guidelines because of lack of prospective evidence. To address this critical gap, TAILOR-PCI (Tailored Antiplatelet Initiation to Lessen Outcomes due to Decreased Clopidogrel Response After Percutaneous Coronary Intervention) is a large, pragmatic, randomized trial comparing point-of-care genotype-guided antiplatelet therapy with routine care to determine whether identifying CYP2C19 loss-of-function allele patients prospectively and prescribing alternative antiplatelet therapy is beneficial.
Prognostic significance of human telomerase reverse transcriptase promoter region mutations C228T and C250T for overall survival in spinal chordomas
Yip, Stephen , Jiang, Bowen , Wang, Wei‐Lien , Lazáry, Áron , Gambarotti, Marco , Zhang, Ming , Sciubba, Daniel M. , Wolinsky, Jean‐Paul , McCarthy, Edward F. , Germscheid, Niccole, Sahgal, Arjun , Gokaslan, Ziya L. , Fisher, Charles G. , Rhines, Laurence D. , Lazary, Aron , Bettegowda, Chetan , Clarke, Michelle J. , Goodwin, C. Rory , Boriani, Stefano , Varga, Péter

Mayo Clinic

Neuro-Oncology | April 8, 2019 | Volume: 21 | Issue: 8 | Pages: 1005-1015

10.1093/neuonc/noz066 | PMID 30976795 Get It

Abstract Background Spinal chordomas, a subtype of primary spinal column malignancies (PSCM), are rare tumors with poor prognosis, and we have limited understanding of the molecular drivers of neoplasia. Methods Study design was a retrospective review of prospectively collected data with cross-sectional survival. Archived paraffin embedded pathologic specimens were collected for 133 patients from 6 centers within Europe and North America between 1987 and 2012. Tumor DNA was extracted and the human telomerase reverse transcriptase (hTERT) promoter was sequenced. The hTERT mutational status was correlated with overall survival (OS) and time to first local recurrence. Results Ninety-two chordomas, 26 chondrosarcomas, 7 osteosarcomas, 3 Ewing’s sarcomas, and 5 other malignant spinal tumors were analyzed. Median OS following surgery was 5.8 years (95% CI: 4.6 to 6.9) and median time to first local recurrence was 3.9 years (95% CI: 2.5 to 6.7). Eight chordomas, 2 chondrosarcomas, 1 Ewing’s sarcoma, and 1 other malignant spinal tumor harbored either a C228T or C250T mutation in the hTERT promoter. In the overall cohort, all patients with hTERT mutation were alive at 10 years postoperative with a median OS of 5.1 years (95% CI: 4.5 to 6.6) (P = 0.03). hTERT promoter mutation was observed in 8.7% of spinal chordomas, and 100% of chordoma patients harboring the mutation were alive at 10 years postoperative compared with 67% patients without the mutation (P = 0.05). Conclusions We report for the first time that hTERT promoter mutations C228T and C250T are present in approximately 8.7% of spinal chordomas. The presence of hTERT mutations conferred a survival benefit and could potentially be a valuable positive prognostic molecular marker in spinal chordomas.
Microglial proliferation and monocyte infiltration contribute to microgliosis following status epilepticus
Feng, Lijie , Murugan, Madhuvika , Bosco, Dale B. , Peng, Jiyun , Ta, Lauren E., Richardson, Jason R. , Shen, Yuxian , Wu, Long‐Jun , Wang, Hai‐Long , Wu, Long-Jun , Liu, Yong , Worrell, Gregory A. , Wang, Hai‐Long

Mayo Clinic

Glia | April 6, 2019 | Volume: 67 | Issue: 8 | Pages: 1434-1448

10.1002/glia.23616 | PMID 31179602 Get It

AbstractMicroglial activation has been recognized as a major contributor to inflammation of the epileptic brain. Seizures are commonly accompanied by remarkable microgliosis and loss of neurons. In this study, we utilize the CX3CR1GFP/+ CCR2RFP/+ genetic mouse model, in which CX3CR1+ resident microglia and CCR2+ monocytes are labeled with GFP and RFP, respectively. Using a combination of time‐lapse two‐photon imaging and whole‐cell patch clamp recording, we determined the distinct morphological, dynamic, and electrophysiological characteristics of infiltrated monocytes and resident microglia, and the evolution of their behavior at different time points following kainic acid‐induced seizures. Seizure activated microglia presented enlarged somas with less ramified processes, whereas, infiltrated monocytes were smaller, highly motile cells that lacked processes. Moreover, resident microglia, but not infiltrated monocytes, proliferate locally in the hippocampus after seizure. Microglial proliferation was dependent on the colony‐stimulating factor 1 receptor (CSF‐1R) pathway. Pharmacological inhibition of CSF‐1R reduced seizure‐induced microglial proliferation, which correlated with attenuation of neuronal death without altering acute seizure behaviors. Taken together, we demonstrated that proliferation of activated resident microglia contributes to neuronal death in the hippocampus via CSF‐1R after status epilepticus, providing potential therapeutic targets for neuroprotection in epilepsy.
Synonymous but Not Silent: A Synonymous VHL Variant in Exon 2 Confers Susceptibility to Familial Pheochromocytoma and von Hippel-Lindau Disease
Flores, Shahida K., Cheng, Ziming , Jasper, Angela M. , Natori, Keiko, Okamoto, Takahiro , Tanabe, Akiyo , Gotoh, Koro , Shibata, Hirotaka , Sakurai, Akihiro , Nakai, Takuya , Wang, Xiaojing , Zethoven, Magnus, Balachander, Shiva , Aita, Yuichi, Takekoshi, Kazuhiro, Nakamura, Eijiro , Tothill, Richard W. , Aguiar, Ricardo C.T. , Dahia, Patricia L M , Young, William F. , Zheng, Siyuan , Dahia, Patricia L. M.

Mayo Clinic

The Journal of Clinical Endocrinology & Metabolism | April 4, 2019 | Volume: 104 | Issue: 9 | Pages: 3826-3834

10.1210/jc.2019-00235 | PMID 30946460 Get It

Abstract Context von Hippel-Lindau (VHL) disease, comprising renal cancer, hemangioblastoma, and/or pheochromocytoma (PHEO), is caused by missense or truncating variants of the VHL tumor-suppressor gene, which is involved in degradation of hypoxia-inducible factors (HIFs). However, the role of synonymous VHL variants in the disease is unclear. Objective We evaluated a synonymous VHL variant in patients with familial PHEO or VHL disease without a detectable pathogenic VHL mutation. Design We performed genetic and transcriptional analyses of leukocytes and/or tumors from affected and unaffected individuals and evaluated VHL splicing in existing cancer databases. Results We identified a synonymous VHL variant (c.414A>G, p.Pro138Pro) as the driver event in five independent individuals/families with PHEOs or VHL syndrome. This variant promotes exon 2 skipping and hence, abolishes expression of the full-length VHL transcript. Exon 2 spans the HIF-binding domain required for HIF degradation by VHL. Accordingly, PHEOs carrying this variant display HIF hyperactivation typical of VHL loss. Moreover, other exon 2 VHL variants from the The Cancer Genome Atlas pan-cancer datasets are biased toward expression of a VHL transcript that excludes this exon, supporting a broader impact of this spliced variant. Conclusion A recurrent synonymous VHL variant (c.414A>G, p.Pro138Pro) confers susceptibility to PHEO and VHL disease through splice disruption, leading to VHL dysfunction. This finding indicates that certain synonymous VHL variants may be clinically relevant and should be considered in genetic testing and surveillance settings. The observation that other coding VHL variants can exclude exon 2 suggests that dysregulated splicing may be an underappreciated mechanism in VHL-mediated tumorigenesis.
MAGI1 as a link between endothelial activation and ER stress drives atherosclerosis
Abe, Jun‐ichi , Ko, Kyung Ae , Kotla, Sivareddy , Paez‐Mayorga, Jesus , Shin, Ik Jae , Imanishi, Masaki , Vu, Hang Thi, Tao, Yunting, Leiva‐Juárez, Miguel M. , Thomas, Tamlyn , Medina, Jan L., Won, Jong Hak, Fujii, Yuka , Giancursio, Carolyn J., McBeath, Elena , Shin, Ji-Hyun, Guzman, Liliana , Abe, Rei , Taunton, Jack , Faubion, William A. , Fujiwara, Keigi , Evans, Scott E. , Le, Nhat‐Tu , Faubion, William, Abe, Rei J , Kotla, Sivareddy , Abe, Jun-Ichi , Wang, Yin , Shin, Ji‐Hyun , Mochizuki, Naoki , Cooke, John P. , Le, Nhat-Tu

Mayo Clinic

JCI Insight | April 3, 2019 | Volume: 4 | Issue: 7 | Pages: No page available

10.1172/jci.insight.125570 | PMID 30944250 Get It

The possible association between the membrane-associated guanylate kinase with inverted domain structure-1 (MAGI1) and inflammation has been suggested, but the molecular mechanisms underlying this link, especially during atherogenesis, remain unclear. In endothelial cells (ECs) exposed to disturbed flow (d-flow), p90 ribosomal S6 kinase (p90RSK) bound to MAGI1, causing MAGI1-S741 phosphorylation and sentrin/SUMO-specific protease 2 T368 phosphorylation-mediated MAGI1-K931 deSUMOylation. MAGI1-S741 phosphorylation upregulated EC activation via activating Rap1. MAGI1-K931 deSUMOylation induced both nuclear translocation of p90RSK-MAGI1 and ATF-6-MAGI1 complexes, which accelerated EC activation and apoptosis, respectively. Microarray screening revealed key roles for MAGI1 in the endoplasmic reticulum (ER) stress response. In this context, MAGI1 associated with activating transcription factor 6 (ATF-6). MAGI1 expression was upregulated in ECs and macrophages found in atherosclerotic-prone regions of mouse aortas as well as in the colonic epithelia and ECs of patients with inflammatory bowel disease. Further, reduced MAGI1 expression in Magi1 –/+ mice inhibited d-flow–induced atherogenesis. In sum, EC activation and ER stress–mediated apoptosis are regulated in concert by two different types of MAGI1 posttranslational modifications, elucidating attractive drug targets for chronic inflammatory disease, particularly atherosclerosis.